Oseltamivir - Roche

Drug Profile

Oseltamivir - Roche

Alternative Names: EN 241104; GS 4104; GS 4104-002; Ke Wei; Kewei; Oseltamivir phosphate; RO 640796; RO 640796/002; Tamiflu; Tamiflu Dry Syrup

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Australian National University; Gilead Sciences; University of California at Berkeley
  • Developer Chugai Pharmaceutical; HEC Pharm; Roche
  • Class Acetamides; Antivirals; Cyclohexenes; Esters; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 16 Dec 2016 Preregistration for Influenza virus infections (In infants, In neonates) in Japan (PO)
  • 16 Dec 2016 Chugai Pharmaceutical files a public-knowledge based application with the Ministry of Health, Labour and Welfare (MHLW), Japan for the approval of oseltamivir for treatment of influenza type A or B virus infection in infants and newborns in Japan
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-virus-infections(In children, In infants) in Israel (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top